164 related articles for article (PubMed ID: 25320178)
1. The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease.
Fu YP; Kohaar I; Moore LE; Lenz P; Figueroa JD; Tang W; Porter-Gill P; Chatterjee N; Scott-Johnson A; Garcia-Closas M; Muchmore B; Baris D; Paquin A; Ylaya K; Schwenn M; Apolo AB; Karagas MR; Tarway M; Johnson A; Mumy A; Schned A; Guedez L; Jones MA; Kida M; Hosain GM; Malats N; Kogevinas M; Tardon A; Serra C; Carrato A; Garcia-Closas R; Lloreta J; Wu X; Purdue M; Andriole GL; Grubb RL; Black A; Landi MT; Caporaso NE; Vineis P; Siddiq A; Bueno-de-Mesquita HB; Trichopoulos D; Ljungberg B; Severi G; Weiderpass E; Krogh V; Dorronsoro M; Travis RC; Tjønneland A; Brennan P; Chang-Claude J; Riboli E; Prescott J; Chen C; De Vivo I; Govannucci E; Hunter D; Kraft P; Lindstrom S; Gapstur SM; Jacobs EJ; Diver WR; Albanes D; Weinstein SJ; Virtamo J; Kooperberg C; Hohensee C; Rodabough RJ; Cortessis VK; Conti DV; Gago-Dominguez M; Stern MC; Pike MC; Van Den Berg D; Yuan JM; Haiman CA; Cussenot O; Cancel-Tassin G; Roupret M; Comperat E; Porru S; Carta A; Pavanello S; Arici C; Mastrangelo G; Grossman HB; Wang Z; Deng X; Chung CC; Hutchinson A; Burdette L; Wheeler W; Fraumeni J; Chanock SJ; Hewitt SM; Silverman DT; Rothman N; Prokunina-Olsson L
Cancer Res; 2014 Oct; 74(20):5808-18. PubMed ID: 25320178
[TBL] [Abstract][Full Text] [Related]
2. Transcription Factor KLF5 Binds a Cyclin E1 Polymorphic Intronic Enhancer to Confer Increased Bladder Cancer Risk.
Pattison JM; Posternak V; Cole MD
Mol Cancer Res; 2016 Nov; 14(11):1078-1086. PubMed ID: 27514407
[TBL] [Abstract][Full Text] [Related]
3. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
Noske A; Brandt S; Valtcheva N; Wagner U; Zhong Q; Bellini E; Fink D; Obermann EC; Moch H; Wild PJ
Oncotarget; 2017 Feb; 8(9):14794-14805. PubMed ID: 27582547
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
5. Association of germline variation in CCNE1 and CDK2 with breast cancer risk, progression and survival among Chinese Han women.
Han JY; Wang H; Xie YT; Li Y; Zheng LY; Ruan Y; Song AP; Tian XX; Fang WG
PLoS One; 2012; 7(11):e49296. PubMed ID: 23185313
[TBL] [Abstract][Full Text] [Related]
6. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
Wu Y; Zheng Q; Li Y; Wang G; Gao S; Zhang X; Yan X; Zhang X; Xie J; Wang Y; Sun X; Meng X; Yin B; Wang B
J Exp Clin Cancer Res; 2019 Aug; 38(1):376. PubMed ID: 31455378
[TBL] [Abstract][Full Text] [Related]
7. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.
Etemadmoghadam D; George J; Cowin PA; Cullinane C; Kansara M; ; Gorringe KL; Smyth GK; Bowtell DD
PLoS One; 2010 Nov; 5(11):e15498. PubMed ID: 21103391
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of the 19q12 amplicon in grade III breast cancers.
Natrajan R; Mackay A; Wilkerson PM; Lambros MB; Wetterskog D; Arnedos M; Shiu KK; Geyer FC; Langerød A; Kreike B; Reyal F; Horlings HM; van de Vijver MJ; Palacios J; Weigelt B; Reis-Filho JS
Breast Cancer Res; 2012 Mar; 14(2):R53. PubMed ID: 22433433
[TBL] [Abstract][Full Text] [Related]
9. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; ; Bowtell D; Waring P
Gynecol Oncol; 2018 Nov; 151(2):327-336. PubMed ID: 30209015
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of 19q12 amplicon in human gastric cancers.
Leung SY; Ho C; Tu IP; Li R; So S; Chu KM; Yuen ST; Chen X
Mod Pathol; 2006 Jun; 19(6):854-63. PubMed ID: 16575401
[TBL] [Abstract][Full Text] [Related]
11. Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma.
Wu S; Chen J; Dong P; Zhang S; He Y; Sun L; Zhu J; Cheng Y; Li X; Tang A; Huang Y; Gui Y; Liu C; Yang G; Zhou F; Cai Z; Wang R
BMC Cancer; 2014 Nov; 14():836. PubMed ID: 25408144
[TBL] [Abstract][Full Text] [Related]
12. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.
Rothman N; Garcia-Closas M; Chatterjee N; Malats N; Wu X; Figueroa JD; Real FX; Van Den Berg D; Matullo G; Baris D; Thun M; Kiemeney LA; Vineis P; De Vivo I; Albanes D; Purdue MP; Rafnar T; Hildebrandt MA; Kiltie AE; Cussenot O; Golka K; Kumar R; Taylor JA; Mayordomo JI; Jacobs KB; Kogevinas M; Hutchinson A; Wang Z; Fu YP; Prokunina-Olsson L; Burdett L; Yeager M; Wheeler W; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Johnson A; Schwenn M; Karagas MR; Schned A; Andriole G; Grubb R; Black A; Jacobs EJ; Diver WR; Gapstur SM; Weinstein SJ; Virtamo J; Cortessis VK; Gago-Dominguez M; Pike MC; Stern MC; Yuan JM; Hunter DJ; McGrath M; Dinney CP; Czerniak B; Chen M; Yang H; Vermeulen SH; Aben KK; Witjes JA; Makkinje RR; Sulem P; Besenbacher S; Stefansson K; Riboli E; Brennan P; Panico S; Navarro C; Allen NE; Bueno-de-Mesquita HB; Trichopoulos D; Caporaso N; Landi MT; Canzian F; Ljungberg B; Tjonneland A; Clavel-Chapelon F; Bishop DT; Teo MT; Knowles MA; Guarrera S; Polidoro S; Ricceri F; Sacerdote C; Allione A; Cancel-Tassin G; Selinski S; Hengstler JG; Dietrich H; Fletcher T; Rudnai P; Gurzau E; Koppova K; Bolick SC; Godfrey A; Xu Z; Sanz-Velez JI; D García-Prats M; Sanchez M; Valdivia G; Porru S; Benhamou S; Hoover RN; Fraumeni JF; Silverman DT; Chanock SJ
Nat Genet; 2010 Nov; 42(11):978-84. PubMed ID: 20972438
[TBL] [Abstract][Full Text] [Related]
13. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract][Full Text] [Related]
14. A miR-151 binding site polymorphism in the 3'-untranslated region of the cyclin E1 gene associated with nasopharyngeal carcinoma.
Liu Y; Cai H; Liu J; Fan H; Wang Z; Wang Q; Shao M; Sun X; Diao J; Liu Y; Shi Y; Fan Q
Biochem Biophys Res Commun; 2013 Mar; 432(4):660-5. PubMed ID: 23416081
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of Bmi1 inhibits bladder cancer cell growth both in vitro and in vivo by blocking cell cycle at G1 phase and inducing apoptosis.
Luo HB; Li B; Yuan WG; Xu CR
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):730-735. PubMed ID: 26489630
[TBL] [Abstract][Full Text] [Related]
16. Identification and replication of the interplay of four genetic high-risk variants for urinary bladder cancer.
Selinski S; Blaszkewicz M; Ickstadt K; Gerullis H; Otto T; Roth E; Volkert F; Ovsiannikov D; Moormann O; Banfi G; Nyirady P; Vermeulen SH; Garcia-Closas M; Figueroa JD; Johnson A; Karagas MR; Kogevinas M; Malats N; Schwenn M; Silverman DT; Koutros S; Rothman N; Kiemeney LA; Hengstler JG; Golka K
Carcinogenesis; 2017 Dec; 38(12):1167-1179. PubMed ID: 29028944
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon.
Lin L; Prescott MS; Zhu Z; Singh P; Chun SY; Kuick RD; Hanash SM; Orringer MB; Glover TW; Beer DG
Cancer Res; 2000 Dec; 60(24):7021-7. PubMed ID: 11156406
[TBL] [Abstract][Full Text] [Related]
18. A functional variant in TP63 at 3q28 associated with bladder cancer risk by creating an miR-140-5p binding site.
Wang M; Du M; Ma L; Chu H; Lv Q; Ye D; Guo J; Gu C; Xia G; Zhu Y; Ding Q; Yuan L; Fu G; Tong N; Qin C; Yin C; Xu J; Zhang Z
Int J Cancer; 2016 Jul; 139(1):65-74. PubMed ID: 26695686
[TBL] [Abstract][Full Text] [Related]
19. Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma.
Nagel I; Akasaka T; Klapper W; Gesk S; Böttcher S; Ritgen M; Harder L; Kneba M; Dyer MJ; Siebert R
Haematologica; 2009 Jul; 94(7):1020-3. PubMed ID: 19454496
[TBL] [Abstract][Full Text] [Related]
20. Association of genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 with the risk of endometrial carcinoma and clinicopathological parameters among Chinese Han women.
Zheng LY; Song AP; Chen L; Liu DG; Li XH; Guo HY; Tian XX; Fang WG
Eur J Obstet Gynecol Reprod Biol; 2015 Jan; 184():65-72. PubMed ID: 25463638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
